跳至主要内容
临床试验/CTIS2022-502912-35-00
CTIS2022-502912-35-00进行中(未招募)1 期

Vaccination against human papillomavirus (HPV) after allogeneic stem cell transplantation, a randomized study between early and late vaccination. - ALLO-HPV

Vastra Gotalandsregionen0 个研究点目标入组 100 人开始时间: 2024年4月25日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)
性别
All

入选标准

  • Recipient of AlloSCT from related or unrelated donor., Adults (men and women) =18 years up to and including 45 years of age for vaccination., Patients can be included regardless of prior HPV vaccination prior to transplantation

排除标准

  • Severe thromobocytopenia (under 50 x 10^9) not allowing intramuscular injektion, Severe acute GvHD grade III-IV., Extensive chronic GvHD requiring treatment with prednisonedoses above 0.7 mg/kg/day plus at least two other systemic treatments against GvHD (for example ruxolitinib or photoferesis)., Prednisonedoses above 1mg/kg/dag at studystart., Treatment with rituximab 6 months before start of vaccination. Doses given later (unusual) do not require exclusion., Treatment within 3 months before start of vaccination with iv or sc immunoglobulin., Pregnancy, pregnancy desire or active pregnancy planning during time vaccine is given and up to three months after last vaccine dose., Treatment with blodthinning medication contraindicating intramuscular injection, Allergy against Gardasil 9

研究者

发起方
Vastra Gotalandsregionen

相似试验